Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

TPEX:7871 Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023
Period Ending	Mar 4, 2026	Dec 31, 2024	Dec 31, 2023
Debt / Equity Ratio	0.04	-1.09	-1.01
Net Debt / Equity Ratio	-0.94	-1.02	-0.98
Net Debt / EBITDA Ratio	2.98	-6.05	-6.34
Net Debt / FCF Ratio	3.16	-5.18	-7.08
Asset Turnover	-	0.01	-
Quick Ratio	20.11	0.07	0.04
Current Ratio	20.16	0.07	0.04
Return on Assets (ROA)	-	-118.27%	-
Return on Invested Capital (ROIC)	-562.92%	-7107.26%	-
Return on Capital Employed (ROCE)	-31.40%	17.40%	16.50%
Buyback Yield / Dilution	-	72.30%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.